Design, synthesis and evaluation of dihydro-1H-indene derivatives as novel tubulin polymerisation inhibitors with anti-angiogenic and antitumor potency

References

• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265.
   PubMed Web of Science ®Google Scholar
• Penna LS, Henriques JAP, Bonatto D. Anti-mitotic agents: are they emerging molecules for cancer treatment? Pharmacol Ther. 2017;173:67–82.
   PubMed Web of Science ®Google Scholar
• Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem. 2004;4(10):1077–1104.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803.
   PubMed Web of Science ®Google Scholar
• Mühlethaler T, Gioia D, Prota AE, Sharpe ME, Cavalli A, Steinmetz MO. Comprehensive analysis of binding sites in tubulin. Angew Chem Int Ed Engl. 2021;60(24):13331–13342.
   PubMed Web of Science ®Google Scholar
• Shuai W, Wang G, Zhang Y, Bu F, Zhang S, Miller DD, Li W, Ouyang L, Wang Y. Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy. J Med Chem. 2021;64(12):7963–7990.
   PubMed Web of Science ®Google Scholar
• Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742.
   PubMed Web of Science ®Google Scholar
• Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S. Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead. Bioorg Med Chem Lett. 2018;28(17):2816–2826.
   PubMed Web of Science ®Google Scholar
• Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers). 2015;7(4):2360–2371.
   PubMed Web of Science ®Google Scholar
• Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ, Cai CY, Vera AA, Zhang L, Chen ZS, Yang DH. Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression. Molecules. 2019;24(23):4383.
   Web of Science ®Google Scholar
• Das T, Anand U, Pandey SK, Ashby CR, Jr., Assaraf YG, Chen ZS, Dey A. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updat. 2021;55:100754.
   PubMed Web of Science ®Google Scholar
• Wang J, Miller DD, Li W. Molecular interactions at the colchicine binding site in tubulin: an X-ray crystallography perspective. Drug Discov Today. 2022;27(3):759–776.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29(11):2943–2971.
   PubMed Web of Science ®Google Scholar
• Tan L, Wu C, Zhang J, Yu Q, Wang X, Zhang L, Ge M, Wang Z, Ouyang L, Wang Y. Design, synthesis, and biological evaluation of heterocyclic-fused pyrimidine chemotypes guided by X-ray crystal structure with potential antitumor and anti-multidrug resistance efficacy targeting the colchicine binding site. J Med Chem. 2023;66(5):3588–3620.
   PubMed Web of Science ®Google Scholar
• Sun M, Zhang Y, Qin J, Ba M, Yao Y, Duan Y, Liu H, Yu D. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization. Bioorg Chem. 2021;113:104988.
   PubMed Web of Science ®Google Scholar
• Liu Z, Huang L, Zhou T, Chang X, Yang Y, Shi Y, Hao M, Li Z, Wu Y, Guan Q, et al. A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non-small cell lung cancers. J Biol Chem. 2022;298(7):102063.
   PubMed Web of Science ®Google Scholar
• Yao Y, Huang T, Wang Y, Wang L, Feng S, Cheng W, Yang L, Duan Y. Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):652–665.
   PubMed Web of Science ®Google Scholar
• Zhu H, Li W, Shuai W, Liu Y, Yang L, Tan Y, Zheng T, Yao H, Xu J, Zhu Z, et al. Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. Eur J Med Chem. 2021;216:113316.
   PubMed Web of Science ®Google Scholar
• Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 1999;81(8):1318–1327.
   PubMed Web of Science ®Google Scholar
• Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem. 2006;49(11):3033–3044.
   PubMed Web of Science ®Google Scholar
• Gaspari R, Prota AE, Bargsten K, Cavalli A, Steinmetz MO. Structural basis of cis- and trans-combretastatin binding to tubulin. Chem. 2017;2(1):102–113.
   Web of Science ®Google Scholar
• Aprile S, Del Grosso E, Tron GC, Grosa G. In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes. Drug Metab Dispos. 2007;35(12):2252–2261.
   PubMed Web of Science ®Google Scholar
• Li W, Sun H, Xu S, Zhu Z, Xu J. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. Future Med Chem. 2017;9(15):1765–1794.
   PubMed Web of Science ®Google Scholar
• Messaoudi S, Tréguier B, Hamze A, Provot O, Peyrat JF, De Losada JR, Liu JM, Bignon J, Wdzieczak-Bakala J, Thoret S, et al. Isocombretastatins a versus combretastatins a: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. J Med Chem. 2009;52(14):4538–4542.
   PubMed Web of Science ®Google Scholar
• Chen J, Ahn S, Wang J, Lu Y, Dalton JT, Miller DD, Li W. Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem. 2012;55(16):7285–7289.
   PubMed Web of Science ®Google Scholar
• Schwikkard S, Whitmore H, Sishtla K, Sulaiman RS, Shetty T, Basavarajappa HD, Waller C, Alqahtani A, Frankemoelle L, Chapman A, et al. The antiangiogenic activity of naturally occurring and synthetic homoisoflavonoids from the hyacinthaceae (sensu APGII). J Nat Prod. 2019;82(5):1227–1239.
   PubMed Web of Science ®Google Scholar
• Galli U, Travelli C, Aprile S, Arrigoni E, Torretta S, Grosa G, Massarotti A, Sorba G, Canonico PL, Genazzani AA, et al. Design, synthesis, and biological evaluation of combretabenzodiazepines: a novel class of anti-tubulin agents. J Med Chem. 2015;58(3):1345–1357.
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6 Suppl 16):15–18.
   PubMed Web of Science ®Google Scholar
• Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6(6):449–458.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–529.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Hassan AMA, Elkaeed EB, Alesawy MS, Al-Karmalawy AA. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorg Chem. 2022;123:105770.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Hemdan MM, Atta-Allah SR. An efficient one-pot synthesis of new Coumarin derivatives as potent anticancer agents under microwave irradiation. J Heterocyclic Chem. 2017;54(6):3519–3526.
   Web of Science ®Google Scholar
• Al-Muntaser SM, Al-Karmalawy AA, El-Naggar AM, Ali AK, Abd El-Sattar NEA, Abbass EM. Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC Adv. 2023;13(18):12184–12203.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002;83(1):21–38.
   PubMed Web of Science ®Google Scholar
• Pérez-Pérez MJ, Priego EM, Bueno O, Martins MS, Canela MD, Liekens S. Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth. J Med Chem. 2016;59(19):8685–8711.
   PubMed Web of Science ®Google Scholar
• Li W, Sun H, Xu F, Shuai W, Liu J, Xu S, Yao H, Ma C, Zhu Z, Xu J. Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site, Bioorg. Bioorg Chem. 2019;85:49–59.
   PubMed Web of Science ®Google Scholar
• Li W, Xu F, Shuai W, Sun H, Yao H, Ma C, Xu S, Yao H, Zhu Z, Yang D-H, et al. Discovery of novel quinoline–chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity. J Med Chem. 2019;62(2):993–1013.
   PubMed Web of Science ®Google Scholar
• Li W, Shuai W, Xu F, Sun H, Xu S, Yao H, Liu J, Yao H, Zhu Z, Xu J. Discovery of novel 4-arylisochromenes as anticancer agents inhibiting tubulin polymerization. ACS Med Chem Lett. 2018;9(10):974–979.
   PubMed Web of Science ®Google Scholar
• Zhu H, Sun H, Liu Y, Duan Y, Liu J, Yang X, Li W, Qin S, Xu S, Zhu Z, et al. Design, synthesis and biological evaluation of vinyl selenone derivatives as novel microtubule polymerization inhibitors. Eur J Med Chem. 2020;207:112716.
   PubMed Web of Science ®Google Scholar
• Hu X, Li L, Zhang Q, Wang Q, Feng Z, Xu Y, Xia Y, Yu L. Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site. Bioorg Chem. 2020;97:103695.
   PubMed Web of Science ®Google Scholar
• Peng X, Ren Y, Pan W, Liu J, Chen J. Discovery of novel acridane-based tubulin polymerization inhibitors with anticancer and potential immunomodulatory effects. J Med Chem. 2023;66(1):627–640.
   PubMed Web of Science ®Google Scholar
• Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des. 2000;6(4):379–392.
   PubMed Web of Science ®Google Scholar
• Leng J, Zhao Y, Sheng P, Xia Y, Chen T, Zhao S, Xie S, Yan X, Wang X, Yin Y, et al. Discovery of novel N-heterocyclic-fused deoxypodophyllotoxin analogues as tubulin polymerization inhibitors targeting the colchicine-binding site for cancer treatment. J Med Chem. 2022;65(24):16774–16800.
   PubMedGoogle Scholar
• Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R., Kshitiz, Systems biology of cancer metastasis. Cell Syst. 2019;9(2):109–127.
   PubMed Web of Science ®Google Scholar
• Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther. 2020;5(1):28.
   PubMed Web of Science ®Google Scholar
• Sana S, Reddy VG, Reddy TS, Tokala R, Kumar R, Bhargava SK, Shankaraiah N. Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: synthesis, in silico and cell growth inhibition studies. Bioorg Chem. 2021;110:104765.
   PubMed Web of Science ®Google Scholar
• Parupalli R, Akunuri R, Spandana A, Phanindranath R, Pyreddy S, Bazaz MR, Vadakattu M, Joshi SV, Bujji S, Gorre B, et al. Synthesis and biological evaluation of 1-phenyl-4,6-dihydrobenzo[b]pyrazolo[3,4-d]azepin-5(1H)-one/thiones as anticancer agents. Bioorg Chem. 2023;135:106478.
   PubMed Web of Science ®Google Scholar
• Huang W, Wu Y, Cheng D, He Z. Mechanism of epithelial‑mesenchymal transition inhibited by miR‑203 in non‑small cell lung cancer. Oncol Rep. 2020;43(2):437–446.
   PubMed Web of Science ®Google Scholar
• Sana S, Reddy VG, Bhandari S, Reddy TS, Tokala R, Sakla AP, Bhargava SK, Shankaraiah N. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. Eur J Med Chem. 2020;200:112457.
   PubMed Web of Science ®Google Scholar
• Zhu H, Tan Y, He C, Liu Y, Duan Y, Zhu W, Zheng T, Li D, Xu J, Yang DH, et al. Discovery of a novel vascular disrupting agent inhibiting tubulin polymerization and HDACs with potent antitumor effects. J Med Chem. 2022;65(16):11187–11213.
   PubMed Web of Science ®Google Scholar